ArticleJournal of general internal medicine2026
Long-Term Opioid Therapy Tapering and Risk of Substance Use Disorder and Overdose: Differences by Opioid Dose and Duration.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTapering from long-term opioid therapy (LTOT) for chronic pain is increasingly common. However, there is inadequate evidence regarding the possibility of adverse effects, particularly across heterogeneous LTOT courses.
objectiveTo estimate associations of tapering from various LTOT doses and durations with risk of substance use disorder (SUD) and overdose.
designWithin-individual cohort study.
participantsUS adults tapering from at least 3 months of stable LTOT, obtained from Optum's de-identified Clinformatics® Data Mart Database for 2010-2021. MAIN MEASURES: Dose tapering was defined as 2 consecutive months of ≥ 15% lower dose within 6 months of LTOT baseline without abrupt discontinuation. Outcomes were assessed from emergency department or inpatient events with recorded SUD or overdose diagnoses. We compared risk of SUD/overdose across up to 1 year following tapering onset with risk during stable LTOT using conditional logistic regression with time-varying covariates. KEY
resultsOf 732,038 adults who experienced an LTOT taper, 7.6% had at least 1 SUD/overdose event during LTOT baseline or up to 1 subsequent year. Relative to LTOT baseline, odds of SUD/overdose were comparably greater in the month before taper onset (odds ratio [OR], 1.36; 95% CI, 1.32, 1.40) and the first month of tapering (OR, 1.38; 95% CI, 1.34, 1.43). Odds decreased partially across the subsequent year (e.g., month 12: OR, 1.11; 95% CI, 1.07, 1.15). This pattern was consistently observed across groups defined by baseline LTOT dose and duration, although odds returned to baseline levels within approximately 6 months of taper onset for those tapering from higher dose (≥ 90 MME/day) and/or longer duration (≥ 12 months) LTOT.
conclusionsThis within-individual study found that LTOT recipients who experienced a dose taper had greater risk of SUD or overdose around the onset of the taper. Much of that risk escalation may precede-rather than result from-changes in monthly dose.
Indexed as
Identifiers
42343056What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.